Search for: "Ranbaxy Laboratories Limited " Results 1 - 20 of 47
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
6 Apr 2015, 7:51 am by Lawrence B. Ebert
The agreement is subject to customary regulatory review, Sun Pharmaceutical Industries said.Meanwhile, trading in shares of Ranbaxy Laboratories was suspended from today, 6 April 2015 as the swap ratio of Ranbaxy Laboratories and Sun Pharmaceutical Industries became effective after Sun Pharmaceutical Industries completed the merger of Ranbaxy Laboratories with itself.Sun Pharmaceutical Industries has set 7 April 2015 as the record date in order… [read post]
10 Jun 2013, 11:23 am
Kumar also disclosed to Thakur that the fabricated test results were not limited to the ARVs Ranbaxy had been producing; rather inventing false data and covering up original test data had been a common practice throughout the company for years. [read post]
21 May 2013, 2:26 pm by Fraud Fighters
Earlier this month, the Department of Justice announced a $500 million settlement it reached with Ranbaxy USA Inc., a subsidiary of the Indian generic pharmaceutical manufacturer Ranbaxy Laboratories Limited. [read post]
26 Feb 2009, 8:23 am
Yesterday, the FDA announced that a facility owned by Ranbaxy Laboratories falsified data and test results in approved and pending drug applications. [read post]
14 May 2013, 10:50 am
Ranbaxy USA Inc., the American subsidiary of Ranbaxy Laboratories Limited, an Indian generic pharmaceutical maker, has agreed to pay $500 million to settle fines related to claims that it made false statements to the FDA about its manufacturing practices abroad and sold substandard medications and pay penalties. [read post]
16 Jul 2010, 8:43 am by Michael C. Smith
Apr. 11, 2008) (limiting Rule 9(b) to allegations of fraud and mistake)]".Finally, Ranbaxy claimed that the complaint failed to plead that the alleged false marking was used in advertising. [read post]
4 Aug 2006, 8:56 am
Ranbaxy Laboratories (06-1179), held that a violation of § 112, ¶ 4 renders a patent invalid even if it would have been merely objected to (and not rejected) by the U.S. [read post]
16 Apr 2018, 2:48 pm by Lawrence B. Ebert
Ranbaxy Laboratories Ltd., Ranbaxy soughtto limit a claim depicting a specific three-dimensionalorientation to a racemic mixture. 457 F.3d 1284, 1288–89(Fed. [read post]
14 Jun 2012, 8:47 am by Aurelia J. Schultz
Shailesh Pednekar, General Manager, ARV Business and Global Therapy Management, Ranbaxy Laboratories Limited. [read post]
24 May 2021, 7:34 am by Deb Givens
  A federal judge has approved multiple classes in litigation accusing Indian generic drugmaker Ranbaxy Laboratories Ltd of delaying the launch of generic drugs by submitting false applications to U.S. regulators. [read post]
3 Mar 2013, 12:06 pm by Rajiv Kr. Choudhry
Patil 337/DELNP/2003 LANXESS DEUTSCHLAND GMBH Granted Dr.Rajesh Dixit 4069/DELNP/2006 RANBAXY LABORATORIES LIMITED Withdrawn Hardev Karar 106/DELNP/2008 ALFA WASSERMANN S. [read post]
18 Feb 2014, 12:43 pm by Dennis Crouch
Ranbaxy Laboratories Ltd., 457 F.3d 1284 (Fed. [read post]
30 Jun 2013, 1:12 pm by Sai Vinod
Interestingly, two of studies were conducted in a laboratory and the other did not measure half-life at all. [read post]
10 Oct 2013, 8:42 am by Jonathan Tycko
Ranbaxy USA Inc. ($500 Million) Ranbaxy USA Inc., a subsidiary of Indian generic pharmaceutical manufacturer Ranbaxy Laboratories Limited, agreed to pay a total of $500 million to settle criminal and civil allegations filed against the company. [read post]
29 Aug 2012, 10:09 pm by FDABlog HPM
(“Merck”) (formerly Schering-Plough Corporation) restricted competition in violation of the Sherman Act by settling patent infringement lawsuits against potential generic K-DUR entrants, including Upsher-Smith Laboratories (“Upsher-Smith”). [read post]
25 Oct 2014, 9:01 pm
Hill-Rom argued that adding this limitation overcame the obviousness rejection because this added limitation was not disclosed in the Ulrich reference[.] [read post]